Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany discusses the upcoming CLL2-GIVe trial on chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) held in Cologne, Germany. Prof. Stilgenbauer first points out that we are living in exciting times for CLL at the moment. There are a number of new agents available such as novel antibodies (e.g. obinutuzumab), BTK inhibitors and BCL2 antagonists. The question therefore is if we still need chemotherapy. The CLL2-GIVe trial, which is about to start, will look at frontline treatment with ibrutinib plus venetoclax plus obinutuzumab (GA101) of patients with 17p deletions or TP53 mutations (NCT02758665). Therefore, this is a chemotherapy-free combination and the aim is to achieve deep and durable remissions.